Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto, Estefania Vangelie Ramos Campos, Maria del Pilar Rodriguez-Torres, Laura Susana Acosta-Torres, Luis Armando Diaz-Torres, Renato Grillo, Mallappa Kumara Swamy, Shivesh Sharma, Solomon Habtemariam, Han-Seung Shin
5 min
Nanomedicine represents a transformative approach to disease treatment and diagnosis by utilizing materials at the nanoscale (1–100 nm). By engineering drug delivery systems at this level, researchers can overcome traditional pharmacological barriers, such as poor water solubility, low absorption, and rapid systemic clearance. This review highlights how nanotechnology bridges the gap between physical and biological sciences to create precise, target-oriented therapeutic interventions.
Nanocarriers function by encapsulating or conjugating therapeutic agents, allowing them to circulate longer in the bloodstream and accumulate at disease sites—often through the enhanced permeability and retention (EPR) effect. These systems can be designed for passive targeting or active targeting, where ligands like antibodies or peptides are attached to the nanoparticle surface to bind specifically to diseased cells. Furthermore, stimuli-responsive nanocarriers have been developed to release drugs in response to external triggers such as pH changes, magnetic fields, light, or temperature, ensuring that the medication is delivered only where and when it is needed.
There is a growing synergy between nanotechnology and natural product-based drug discovery. Many potent natural compounds, such as curcumin and quercetin, suffer from poor bioavailability and stability. Encapsulating these compounds in nanocarriers like liposomes, dendrimers, or polymeric nanoparticles significantly improves their therapeutic potential. Additionally, the field of theranostics—the integration of therapy and diagnostic imaging into a single platform—is a major focus. These multifunctional nanoparticles allow clinicians to simultaneously detect a tumor, monitor its location, and deliver a precise dose of chemotherapy, providing a more personalized approach to cancer treatment.
Despite the promise of nanomedicine, the field faces significant hurdles. The lack of standardized protocols for characterizing nanomaterials and assessing their long-term toxicity remains a primary barrier to widespread clinical adoption. Furthermore, the regulatory landscape is still evolving, with many products currently in clinical trials but few fully approved. Future research must prioritize the development of more uniform, stable, and biocompatible nanocarriers, alongside rigorous, multi-center studies to ensure the safety and efficacy of these advanced medical tools.
Nanomedicine and nano delivery systems are a relatively new but rapidly developing science where materials in the nanoscale range are employed to serve as means of diagnostic tools or to deliver therapeutic agents to specific targeted sites in a controlled manner. Nanotechnology offers multiple benefits in treating chronic human diseases by site-specific, and target-oriented delivery of precise medicines. Recently, there are a number of outstanding applications of the nanomedicine (chemotherapeutic agents, biological agents, immunotherapeutic agents etc.) in the treatment of various diseases. The current review, presents an updated summary of recent advances in the field of nanomedicines and nano based drug delivery systems through comprehensive scrutiny of the discovery and application of nanomaterials in improving both the efficacy of novel and old drugs (e.g., natural products) and selective diagnosis through disease marker molecules. The opportunities and challenges of nanomedicines in drug delivery from synthetic/natural sources to their clinical applications are also discussed. In addition, we have included information regarding the trends and perspectives in nanomedicine area.
Alex: [curious] Stepping back to the release step itself—if these carriers are stable enough to survive circulation, how do they reliably dump the drug only at the tumor site without leaking along the way?
Sam: [measured, teaching mode] That's controlled release, and the logic is essentially a molecular switch. The carrier is stable while circulating, but undergoes a structural collapse or bond cleavage when it meets a specific microenvironmental trigger. Since many tumors run more acidic than surrounding tissue, researchers build polymers that get protonated at that lower pH—the polymer swells or dissolves, and the drug is forced out. It's a chemical logic gate keyed to the tumor's own chemistry. [[RP_SECTION:protein-corona-and-stealth|Protein Corona and Stealth]]
Alex: [processing] Elegant, but surely there's a cost. Does bolting on all these sensing groups make the particle more visible to the immune system?
Sam: [grounded, acknowledging the trade-off] That's the primary bottleneck the review flags. Every functional group you add changes the surface chemistry, and that tends to produce a protein corona—blood proteins coating the nanoparticle almost immediately. That corona can trigger clearance before the carrier reaches the tumor, and it can also physically mask the targeting ligands you spent effort engineering.
Alex: [deliberate] So the more targeting features you pack on, the more likely the immune system is to flag the whole thing as foreign.
Sam: [nodding] Precisely—it's a constant trade-off between specificity and stealth. That's part of why natural biopolymers like hyaluronic acid get so much attention; they're more biocompatible. But even there, uptake isn't standardized. Cells take these particles up through endocytosis, and the kinetics shift substantially with size and surface charge, which makes cross-study comparison difficult.
Alex: [leaning back] It sounds like the field has the tools to build complex, responsive vehicles, but not yet a reliable way to predict how any given design behaves once it's inside a living system. [[RP_SECTION:clinical-translation-challenges|Clinical Translation Challenges]]
Sam: [measured] That's a fair read. And it connects to where the field sits clinically. There are dozens of FDA-approved nanomedicines now, but most are still reformulations of established drugs—better pharmacokinetics for known agents, rather than genuinely new therapeutic logic.
Alex: [probing] So largely old drugs in smarter packaging, rather than a new class of treatment.
Sam: [precise] Largely, yes. And the protein corona problem we just discussed is a big reason why—it doesn't just affect clearance, it alters the particle's effective identity once it's in the bloodstream, which makes standardized regulatory evaluation genuinely difficult. Without agreed protocols for characterizing these materials under physiological conditions, you're partly guessing how a given design will behave systemically. The review's argument is that progress from here depends less on adding more functional complexity to the carriers, and more on building predictive models of these biological barriers—corona formation, clearance, heterogeneous tumor environments—so design choices made on the bench actually hold up in vivo.
Alex: [reflective] So the next phase of the field is less about cleverer nanoparticles and more about understanding the biology well enough to know which clever designs will actually survive contact with it.
Sam: [calm] That's the consensus the review lands on. If you want the figures, the specific method choices, and the full breakdown of the regulatory hurdles we didn't walk through here, you can generate a deep dive of this paper. The paper has the rest either way.
Alex: [warmly] Thanks for listening.